Advanced or Metastatic Clear Cell Renal Cell CarcinomaPhase 1NCT07564232
LNK001 Dual-Target CAR T Cells
LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Drug Screening Using Novel IMD in Renal Cell Carcinoma
What the film says
This trial is for adults with kidney cancer that has spread, who are having surgery to remove a tumor.
The idea: before surgery, a tiny device is placed into the tumor through a needle. It has twenty small reservoirs that release very small doses of standard cancer drugs and combinations. When the tumor is removed, the tissue around each reservoir shows how the cancer responded to each drug.
The study looks at whether placing and retrieving the device is safe and feasible.
This phase 1 study plans 20 patients. At Dana-Farber Cancer Institute in Boston, Wenxin Xu leads it.
Public record; not medical advice.
Sources behind this film
Adults; metastatic RCC; surgery; Device via needle; 20 microreservoirs; microdoses of standard drugs; Tissue shows response; Safety and feasibility of implanting and retrieving (+1 more lines)
The drug
Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.
This Pilot research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC).
The drugs participants receive will include medications currently used as standard-of-care treatment for metastatic RCC as well as medications currently approved in other cancer types that are under investigation for treatment of RCC. * This study involves planting one or more microdevices, each small enough to fit inside the tip of a needle, into a tumor. The microdevices will release microdoses of cancer drugs via passive diffusion.
The study
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC).
The name of the intervention(s) involved in this study are: * Implantable Microdevice (IMD) * Surgery (excision of tumor) * Drugs used in this study will only include drugs already used as standard of care for the treatment of metastatic renal cell carcinoma (RCC)
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.